Nov 13, 2025 11:26 AM Eastern Standard Time Pfizer Completes Acquisition of Metsera Share NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are ...

Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bi... ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-42489 METSERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 92-0931552 (State or othe ...

U.S. equities staged a robust comeback on Monday, November 10, 2025, with major indexes posting significant gains as investors shrugged off last week's losses and embraced renewed optimism surrounding a potential resolution to the prolonged government shutdown. A powerful rally in Big Tech and artificial intelligence (AI) stocks fueled the market's ascent, overshadowing some declines in the healthcare sector.Market Performance Recap: A Strong Start to the WeekThe trading day saw a broad-based rally, with al ...

Mergers and Acquisitions - Pfizer agreed to acquire Metsera, a weight-loss drug start-up, for up to $86.25 per share, valuing the deal at over $10 billion. Pfizer will pay $65.60 in cash per share and additional contingent payments of up to $20.65 per share [3][4] - Metsera's board stated that Pfizer's revised bid represents the best transaction for shareholders in terms of value and certainty of closing, surpassing a previous bid from Novo Nordisk [3] Stock Movements - Metsera's stock dropped 15% to $70.75 following the acquisition announcement [3] - Nvidia's shares rose 3.1% after a 7% decline the previous week, attributed to optimism regarding the end of the government shutdown [5] - Tesla's stock gained 2.2% after a 3.7% decline on Friday, following shareholder approval of a significant pay package for CEO Elon Musk [6] Earnings Reports and Guidance - CoreWeave is expected to report quarterly earnings, with analysts predicting a loss of $0.40 per share on revenue of $1.26 billion [11] - Monday.com declined 15% after reporting third-quarter earnings that exceeded estimates but provided fourth-quarter revenue guidance below expectations [9] Other Notable Developments - Rumble's stock rose 17% after announcing an agreement to acquire Northern Data for up to $970 million [8] - TreeHouse Foods jumped 20% to $22.85 after agreeing to be taken private by Investindustrial in a $2.9 billion all-cash transaction [8] - Visa and Mastercard shares rose 0.2% amid reports of a potential settlement with merchants to lower fees and enhance their negotiating power [10]

Core Insights - The bidding war for Metsera between Pfizer and Novo Nordisk has concluded, with Pfizer acquiring Metsera for $86.25 per share, totaling over $10 billion, significantly higher than the initial offer of $70 per share made in September [1][4][8] Acquisition Details - Pfizer's final offer includes $65.60 per share in cash and a contingent value right (CVR) of up to $20.65 per share, representing a 160% premium over Metsera's closing price prior to Pfizer's first offer [1][4] - The board of directors of Metsera has unanimously recommended that shareholders approve the merger with Pfizer, citing immediate and substantial value [2] - The acquisition is expected to close shortly after the Metsera shareholders' meeting on November 13, following the FTC's early termination of the waiting period under the Hart-Scott-Rodino Antitrust Act [2] Competitive Landscape - Novo Nordisk initially proposed an unsolicited offer of $77.75 per share, later increasing it to match Pfizer's final offer of $86.25 per share, but has since withdrawn from the bidding process [4][5] - Pfizer filed lawsuits against Metsera and Novo Nordisk, alleging breach of contract and antitrust violations related to the competing offer from Novo Nordisk [5][6] Strategic Implications - The acquisition of Metsera allows Pfizer to re-enter the obesity treatment market, enhancing its pipeline with four clinical-stage obesity programs, including MET-097i, a GLP-1 receptor agonist [8][9] - Pfizer's previous attempt to develop an obesity drug, danuglipron, was halted earlier this year due to safety concerns, making the Metsera acquisition a strategic move to regain a foothold in this lucrative market [10] Financial Impact - Pfizer anticipates that the acquisition will be dilutive to its adjusted EPS by approximately 16 cents in 2026 and remain dilutive through 2030, but it expects no impact on its 2025 guidance [11] - Pfizer's stock has seen a decline of 7.9% this year, contrasting with a 6.4% increase in the industry [14] Valuation Metrics - Pfizer's shares are currently trading at a forward P/E ratio of 7.8, which is lower than the industry average of 15.57 and its own 5-year mean of 10.52, indicating potential attractiveness from a valuation standpoint [15]

Core Viewpoint - Fizer's acquisition of MSA for up to $10 billion is a strategic move to establish a strong presence in the rapidly growing obesity drug market, following a competitive bidding process with Nova Nordisk [1][2]. Group 1: Acquisition Details - The deal includes a contingent value right (CVR) for MSA shareholders, which will provide additional benefits if certain approval metrics are met [4]. - The additional expenditure of $2.1 billion was justified by the potential for significant value creation in the obesity market, which Fizer believes it can capitalize on effectively [2][3]. Group 2: Market Position and Strategy - Fizer is recognized as a leader in primary care, with strong capabilities in conducting complex studies related to metabolic and cardiovascular conditions, which positions the company well for success in the obesity drug sector [4]. - The company has a robust commercial strategy and manufacturing capabilities, addressing previous bottlenecks in drug production [5]. Group 3: Future Outlook - Fizer's CEO expressed confidence in the likelihood of meeting the CVR targets, citing high probabilities for the success and approval of the new drug molecules [6]. - The company anticipates that its new drug offerings will reach the market within three years, aiming to significantly impact obesity treatment [11]. Group 4: Competitive Landscape - Fizer believes it can effectively compete with established players like Eli Lilly and Novo Nordisk, leveraging its expertise and differentiated product offerings [9][10]. - The company is focused on developing a once-a-month injection for obesity treatment, which it believes will meet patient demand and potentially change the treatment landscape [10]. Group 5: Previous Acquisitions - The acquisition of Cigen, valued at nearly $40 billion, is viewed as transformational for Fizer, enhancing its oncology portfolio and accelerating research and development efforts [12][13].

BREAKING: These S&P 500 Stocks Dive On Fed Shutdown Deal Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience. Metsera (MTSR) stock toppled Monday after the buyout battle with Pfizer (PFE) and Novo Nordisk (NVO) ended. Pfizer will acquire the small obesity-focused biotech company for up to $10 billion. That's up from a total of $4.9 billion when Pfizer first announced its plan to acquire Metsera. Shortly afte ...

Core Insights - The Danish drugmaker's shareholders are relieved that the company has not overpaid for treatments that are largely unproven [1] Company Summary - The company has managed to avoid excessive financial commitments in acquiring treatments that lack substantial evidence of efficacy [1]

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.Dhierin-Perkash Bechai is an aerospace, defense and airline analyst. Dhierin runs the investing group The Aerospace Forum, whose goal is to discover investment opportunities in the aerospace, defense and airline industry. With a background in aeros ...